These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35788962)

  • 1. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
    Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
    Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.
    Petersen CL; Hougaard A; Gaist D; Hallas J
    JAMA Neurol; 2024 Mar; 81(3):248-254. PubMed ID: 38315477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
    Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS
    Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
    Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
    Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice.
    Hall GC; Brown MM; Mo J; MacRae KD
    Neurology; 2004 Feb; 62(4):563-8. PubMed ID: 14981171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
    Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
    J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
    Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Migraine Prescription Patterns Vary by Baseline Cardiovascular Risk and Clinical Characteristics: A Real-World Evidence Study.
    Li H; Vincent M; Zhang X; Dennehy EB; Goodloe R; Aurora SK; Smith TR
    Pain Ther; 2020 Dec; 9(2):499-509. PubMed ID: 32328974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
    Roberto G; Raschi E; Piccinni C; Conti V; Vignatelli L; D'Alessandro R; De Ponti F; Poluzzi E
    Cephalalgia; 2015 Feb; 35(2):118-31. PubMed ID: 25246519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.
    Sacco S; Di Ciaccio S; Di Virgilio R; Pegoraro V; Ornello R
    Neurol Sci; 2024 Sep; 45(9):4427-4435. PubMed ID: 38538924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute migraine treatment with oral triptans and NSAIDs in a managed care population.
    Ng-Mak DS; Hu XH; Chen YT; Ma L
    Headache; 2008 Sep; 48(8):1176-85. PubMed ID: 18819177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
    Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
    J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
    Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
    Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triptan use as a function of cardiovascular risk. A population-based study.
    Bigal ME; Golden W; Buse D; Chen YT; Lipton RB
    Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
    Hyeraci G; Gini R; Bezin J; Iannone LF; Benemei S; Lupi C; De Cesaris F; Geppetti P; Roberto G
    Headache; 2023 Feb; 63(2):222-232. PubMed ID: 36705316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.